The Valsartan lawsuit allows you to seek compensation if you developed certain types of cancer, like bladder or colorectal cancer, after taking the contaminated blood pressure medication. Eligibility depends on your state’s statute of limitations, and you may be able to file on behalf of a deceased loved one. As of May 2025, over 1,300 lawsuits were pending, with the first bellwether trial scheduled for September. To learn more about this complex litigation, continue reading.
Key Takeaways
- The Valsartan lawsuit involves claims of certain types of cancer and liver injury related to the NDMA contamination in certain batches of the drug.
- As of May 2025, there are 1,322 pending valsartan lawsuits in the MDL, with a total of 1,493 Valsartan, Losartan, and Irbesartan cases filed.
- The first bellwether trial is scheduled for September 8, 2025, with expert discovery concluding in May 2025 to prepare for the trial.
- Plaintiffs continue to file Valsartan cancer lawsuits, but the pace of new filings has slowed, with only 5 new cases in November 2024.
- The issue of ZHP’s document production remains a point of contention, impacting the plaintiffs’ ability to build their case.
Eligibility and Qualifying for a Valsartan Lawsuit
If you were diagnosed with certain types of cancer after taking valsartan, you may qualify to file a valsartan cancer lawsuit. Eligible injuries include bladder, colorectal, kidney, liver, pancreatic, and stomach cancer, as well as liver injury. This is because certain batches of the blood pressure drug valsartan were contaminated with NDMA, a probable human carcinogen.
Eligibility depends on your state’s applicable statute of limitations. You may also file a valsartan lawsuit on behalf of a deceased loved one who’d taken the contaminated drug.
Valsartan Lawsuit Updates
The number of pending valsartan lawsuits in the MDL has grown to 1,322 as of May 1, 2025.
Plaintiffs have filed motions to exclude certain experts in the ongoing litigation, while the court has certified classes of plaintiffs including consumer economic loss, medical monitoring, and third-party payor classes.
The first bellwether trial in the valsartan MDL is scheduled to begin on September 8, 2025.
Lawsuit Growth Continues
As the Valsartan multidistrict litigation (MDL) continues to unfold, the number of pending cases has steadily increased. With 12 new cases joining in May 2025, the total now stands at 1,322 pending cases.
This growth extends to the wider litigation, as the total number of Valsartan, Losartan, and Irbesartan cases filed in the MDL reached 1,493 as of the same month. While the pace of new filings has slowed, with only 5 new Valsartan cases added in November 2024, the overall legal landscape remains active, with plaintiffs continuing to file Valsartan cancer lawsuits related to the contaminated valsartan product.
Crucial Document Issues
Zhejiang Huahai Pharmaceutical Co., Ltd. (ZHP), the Chinese manufacturer at the center of the Valsartan recall, has failed to produce multiple documents requested in the ongoing Valsartan multidistrict litigation (MDL). Despite receiving a seven-day extension, ZHP still didn’t provide the requested documentation, negatively impacting the plaintiffs’ ability to build their case.
Judge Renée Marie Bumb rejected ZHP’s motion to reverse or modify the sanctions order against them for failing to produce documents. This issue of ZHP’s document production continues to be a point of contention in the Valsartan litigation, as plaintiffs seek vital information to support their claims.
Bellwether Trials Approach
Steadily, the bellwether trials approach in the Valsartan multidistrict litigation (MDL), signaling a pivotal phase in the ongoing legal battle. The first bellwether trial is set for September 8, 2025, with expert discovery concluding by May 8th to prepare.
The MDL judge is also overseeing a second wave of bellwether trials in case the first doesn’t drive broader settlements. Final pretrial motions are due in July 2025, ahead of the initial trial. Concerns linger over the trial length given the complex nature of the Valsartan litigation, but the legal process continues to move forward.
About Drugwatch.com
You can count on Drugwatch.com for credible health information and dedicated legal assistance. It’s a trusted online resource you can turn to for help with various medical issues.
With an A+ BBB rating and HONCode certification, Drugwatch.com provides high-quality content from professional experts.
Credible Health Information
Drugwatch.com has been a trusted source of reliable health information since 2008. The Drugwatch team includes medical writers, journalists, researchers, and experts who provide objective, fact-based content. Drugwatch is HONCode certified, has a 5-star rating for its medical and legal information, and an A+ rating from the Better Business Bureau.
If you or a loved one has filed valsartan lawsuits, been diagnosed with cancer after taking the blood pressure medication, or are interested in the upcoming bellwether trial, Drugwatch’s credible resources can help you navigate the ongoing multidistrict litigation (MDL) and the first Valsartan trial in the round of bellwether trials.
Dedicated Legal Assistance
Connecting thousands of people with top-ranked national law firms, Drugwatch.com provides dedicated legal assistance to those seeking justice and compensation.
If you’ve been affected by contaminated Valsartan, Drugwatch can connect you with experienced legal professionals to review your medical records and determine if you qualify for the Valsartan Cancer Lawsuit Qualified Settlement Fund.
Trusted Online Resource
As a trusted online resource, Drugwatch.com has been providing reliable health and legal information to the public since 2008. The website’s team includes medical writers, journalists, researchers, and experts, ensuring high-quality information from credible sources. Drugwatch.com is HONCode certified and has an A+ rating from the Better Business Bureau, making it a 5-star reviewed medical and legal information site.
Drugwatch.com has assisted thousands of people in finding top-ranked national law firms for Valsartan lawsuits and other drug-related cases. The website is a valuable resource for those seeking information about Valsartan settlements, new cases, class actions, and the total number of pending lawsuits. Additionally, Drugwatch.com provides information on medical monitoring and the Valsartan multidistrict litigation (MDL) process.
Why People Are Filing Valsartan Lawsuits
Individuals are filing valsartan lawsuits because they claim they developed severe health issues, such as cancer or liver damage, after taking contaminated valsartan drugs. Plaintiffs allege certain drugmakers manufactured defective valsartan containing the probable carcinogen NDMA. They say defendants failed to warn the public about the potential for contaminated valsartan to cause cancer and liver damage.
Some filed valsartan lawsuits as class actions seeking refunds, while personal injury claims allege contaminated valsartan caused various cancers. The Valsartan MDL Case consolidates these claims. Plaintiffs took Valsartan and developed cancer, citing grounds to file due to contamination with NDMA. Law firms represent those in the Valsartan multidistrict litigation (MDL) who claim they were harmed by the probable human carcinogens.
Are Legal Issues in the Valsartan Lawsuit Similar to Those in the Breo Ellipta Lawsuit?
The Valsartan lawsuit and the Breo Ellipta lawsuit both address significant health concerns related to their respective medications. However, while the underlying issues differ, the similar nature of patient grievances highlights a common theme in pharmaceutical litigation. For comprehensive insights, you can look into breo ellipta legal controversy details.
How a Lawyer Can Help and Valsartan Lawsuit Facts
Qualified valsartan lawsuit attorneys can be invaluable in maneuvering the complexities of these cases. They can:
- Review your case, present the scientific evidence, and gather relevant medical records to support your claim.
- Advise on any exceptions to statutes of limitations that may extend the filing deadline.
- Determine the degree of liability for cancer-related injuries based on each defendant’s role in the supply chain.
- Recommend keeping the bottle of contaminated valsartan to help with testing for the carcinogenic impurity NDMA.
Medical records demonstrating use of a recalled valsartan batch can be critical evidence for your lawsuit.
Valsartan MDL Case Updates
The Valsartan MDL continues to grow, with the latest updates showing a significant increase in the number of pending cases. As of May 2025, the MDL has grown to 1,322 pending cases, with the total number of Valsartan cases filed reaching 1,493.
The first Valsartan bellwether trial is scheduled to begin in September 2025, marking a pivotal step in the litigation. The Valsartan MDL is currently consolidated in the U.S. District Court of New Jersey and includes lawsuits involving other blood pressure medications like losartan and irbesartan.
With the tainted Valsartan crisis continuing to unfold, the Valsartan MDL remains a complex and evolving legal landscape.
Conclusion
You’re probably wondering if you qualify for a valsartan lawsuit. Well, let’s not sugarcoat it – the situation’s a real mess. But don’t worry, a good lawyer can sort it out. Just remember – the more lawsuits, the merrier! So why not join the party and cash in on this pharmaceutical fiasco? It’s a win-win, right? Get on it before the gravy train leaves the station.
